Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

v3.5.0.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
BRL in Millions, $ in Millions
9 Months Ended
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Operating activities:    
Consolidated net income $ 370.3 $ 321.8
Adjustments to reconcile consolidated net income to net cash provided by operating activities:    
Impairment of cost method investment 0.0 14.8
Depreciation and amortization 195.4 150.4
Stock-based compensation expense 30.2 32.2
Excess tax benefits from stock-based compensation plans (29.6) (22.1)
Deferred income taxes (10.4) (24.3)
Changes in assets and liabilities, excluding effects of acquisitions:    
Accounts receivable, net (54.5) (29.0)
Prepaid expenses and other current assets 7.0 21.2
Other assets (7.9) 3.9
Current liabilities, excluding debt 1.8 68.0
Other long-term liabilities, excluding debt 22.2 (0.1)
Cash provided by operating activities 524.5 536.8
Investing activities:    
Capital expenditures (131.0) (93.6)
Acquisitions, net of cash acquired (1,792.4) (4.4)
Cash received from divestitures 0.0 2.9
Economic hedges (10.8) 0.0
Investment in unconsolidated affiliates, net 0.0 (0.1)
Cash used in investing activities (1,934.2) (95.2)
Financing activities:    
Net short-term borrowings (repayments) 194.2 (193.4)
Payments on long-term debt (300.0) 0.0
Borrowings on long-term debt 1,574.7 0.0
Treasury stock purchases 0.0 (196.3)
Dividends paid to Equifax shareholders (118.1) (103.4)
Dividends paid to noncontrolling interests (5.8) (6.0)
Proceeds from exercise of stock options 26.8 26.0
Excess tax benefits from stock-based compensation plans 29.6 22.1
Purchase of redeemable noncontrolling interests (3.6) 0.0
Debt issuance costs (5.4) 0.0
Cash provided by (used in) financing activities 1,392.4 (451.0)
Effect of foreign currency exchange rates on cash and cash equivalents 35.5 (10.4)
Increase (decrease) in cash and cash equivalents 18.2 (19.8)
Cash and cash equivalents, beginning of period 93.3 128.3
Cash and cash equivalents, end of period $ 111.5 $ 108.5